Latest Breaking News On - Opaleye management - Page 4 : vimarsana.com

Harrow Health, Inc (NASDAQ:HROW) Expected to Earn Q1 2024 Earnings of ($0 25) Per Share

Harrow Health, Inc. (NASDAQ:HROW – Free Report) – Investment analysts at B. Riley issued their Q1 2024 earnings per share estimates for shares of Harrow Health in a research note issued to investors on Thursday, March 21st. B. Riley analyst M. Mamtani forecasts that the company will post earnings of ($0.25) per share for the […]

Eton pharmaceuticals incGoldman sachs group incHarrow healthNuveen asset managementHarrow health stockBarclays plcSurface ophthalmics incPricet rowe associates incNews ratings for harrow health dailyVanguard group incHedge funds weigh in on harrow healthOpaleye management incHarrow health incPharmaceuticals incFree reportSachs group

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up to $9 69

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up to $9 69
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Arcutis biotherapeuticsOpaleye management incJennison associatesFranklin resources incNeedham companyArcutis biotherapeutics incGoldman sachs groupVanguard group incGet free reportPoint capitalOpaleye management

Ocular Therapeutix (OCUL) Announces $325M Private Placement at $7 52/sh

Ocular Therapeutix (OCUL) Announces $325M Private Placement at $7 52/sh
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesOcular therapeutix incGreat point partnersExchange commissionOcular therapeutixVenrock healthcare capital partnersDeep track capitalPerceptive advisorsLogos capitalSurveyor capitalAcuta capital partnersOpaleye managementSecurities act

Ocular Therapeutix, Inc Announces $325 0 Million Private

BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to.

United statesJoyce allaireDonald notmanOcular therapeutix incExchange commissionGreat point partnersVenrock healthcare capital partnersDeep track capitalPerceptive advisorsLogos capitalSurveyor capitalAcuta capital partnersOpaleye managementSecurities actOcular therapeutixLooking statements

Ocular Therapeutix, Inc Announces $325 0 Million Private Placement

Ocular Therapeutix, Inc Announces $325 0 Million Private Placement
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesJoyce allaireDonald notmanOcular therapeutix incGreat point partnersExchange commissionVenrock healthcare capital partnersDeep track capitalPerceptive advisorsLogos capitalSurveyor capitalAcuta capital partnersOpaleye managementSecurities actOcular therapeutixLooking statements